Anhui Anke BioTech Group (300009) - Total Assets
Based on the latest financial reports, Anhui Anke BioTech Group (300009) holds total assets worth CN¥5.10 Billion CNY (≈ $746.38 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Anhui Anke BioTech Group to assess how comfortably operating cash covers total debt obligations.
Anhui Anke BioTech Group - Total Assets Trend (2006–2024)
This chart illustrates how Anhui Anke BioTech Group's total assets have evolved over time, based on quarterly financial data. See 300009 net asset value for net asset value and shareholders' equity analysis.
Anhui Anke BioTech Group - Asset Composition Analysis
Current Asset Composition (December 2024)
Anhui Anke BioTech Group's total assets of CN¥5.10 Billion consist of 44.3% current assets and 55.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.8% |
| Accounts Receivable | CN¥522.76 Million | 10.2% |
| Inventory | CN¥297.30 Million | 5.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥616.49 Million | 12.0% |
| Goodwill | CN¥66.56 Million | 1.3% |
Asset Composition Trend (2006–2024)
This chart illustrates how Anhui Anke BioTech Group's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Anhui Anke BioTech Group.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anhui Anke BioTech Group's current assets represent 44.3% of total assets in 2024, an increase from 38.5% in 2006.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2024, down from 14.1% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 8.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 12.0% of total assets.
Anhui Anke BioTech Group Competitors by Total Assets
Key competitors of Anhui Anke BioTech Group based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Anhui Anke BioTech Group - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.78 | 3.20 | 3.47 |
| Quick Ratio | 3.32 | 2.77 | 3.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.69 Billion | CN¥1.54 Billion | CN¥1.17 Billion |
Anhui Anke BioTech Group - Advanced Valuation Insights
This section examines the relationship between Anhui Anke BioTech Group's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.93 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | CN¥5.14 Billion |
| Market Capitalization | $2.04 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Anhui Anke BioTech Group's assets below their book value (0.40x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Anhui Anke BioTech Group's assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Anhui Anke BioTech Group (2006–2024)
The table below shows the annual total assets of Anhui Anke BioTech Group from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.14 Billion ≈ $751.46 Million |
+3.73% |
| 2023-12-31 | CN¥4.95 Billion ≈ $724.45 Million |
+16.34% |
| 2022-12-31 | CN¥4.26 Billion ≈ $622.69 Million |
+15.98% |
| 2021-12-31 | CN¥3.67 Billion ≈ $536.90 Million |
+4.69% |
| 2020-12-31 | CN¥3.50 Billion ≈ $512.87 Million |
+8.64% |
| 2019-12-31 | CN¥3.23 Billion ≈ $472.10 Million |
+27.67% |
| 2018-12-31 | CN¥2.53 Billion ≈ $369.77 Million |
+12.10% |
| 2017-12-31 | CN¥2.25 Billion ≈ $329.85 Million |
+14.70% |
| 2016-12-31 | CN¥1.97 Billion ≈ $287.58 Million |
+40.25% |
| 2015-12-31 | CN¥1.40 Billion ≈ $205.05 Million |
+53.05% |
| 2014-12-31 | CN¥915.58 Million ≈ $133.98 Million |
+22.11% |
| 2013-12-31 | CN¥749.81 Million ≈ $109.72 Million |
+14.84% |
| 2012-12-31 | CN¥652.93 Million ≈ $95.54 Million |
+8.16% |
| 2011-12-31 | CN¥603.65 Million ≈ $88.33 Million |
+2.39% |
| 2010-12-31 | CN¥589.55 Million ≈ $86.27 Million |
+8.70% |
| 2009-12-31 | CN¥542.36 Million ≈ $79.36 Million |
+143.25% |
| 2008-12-31 | CN¥222.96 Million ≈ $32.63 Million |
-5.75% |
| 2007-12-31 | CN¥236.55 Million ≈ $34.62 Million |
+4.80% |
| 2006-12-31 | CN¥225.72 Million ≈ $33.03 Million |
-- |
About Anhui Anke BioTech Group
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterf… Read more